There is no widely recognized drug with the exact code "IPX-822." However, it is frequently confused with , a leading investigational small molecule developed by Inipharm .
IPX-822 is a promising viral vector vaccine that has shown efficacy in preclinical studies against COVID-19. Its flexibility, safety, and potency make it an attractive candidate for further development. As research continues to advance, IPX-822 may become an important tool in the fight against COVID-19 and other infectious diseases. IPX-822